Related Experiment Video
Updated: Mar 2, 2026
07:31
Nitropeptide Profiling and Identification Illustrated by Angiotensin II
Published on: June 16, 2019
6.2K
Innovative Therapeutics: Designer Natriuretic Peptides
Laura M G Meems1, John C Burnett1
1Cardiorenal Research Laboratory, Department of Cardiovascular Diseases, College of Medicine Mayo Clinic, Rochester, MN.
JACC. Basic to Translational Science
|May 13, 2017
Summary
Designer natriuretic peptides offer advanced cardiovascular disease treatments. Engineered for enhanced efficacy and delivery, these designer peptides show promise in clinical trials for heart failure and hypertension.
Area of Science:
- Cardiovascular Research
- Peptide Engineering
- Drug Discovery
Background:
- Natriuretic peptides are crucial for maintaining volume homeostasis and are produced by the heart, kidneys, and endothelium.
- These peptides activate particulate guanylyl cyclase receptors and cyclic guanosine monophosphate (cGMP).
- Traditional natriuretic peptides face limitations in efficacy, specificity, and enzymatic stability.
Purpose of the Study:
- To review the conceptual framework of engineering natriuretic peptides into designer peptides.
- To highlight advancements in peptide engineering and delivery systems for cardiovascular therapeutics.
- To provide an update on designer natriuretic peptides in clinical trials for cardiovascular diseases.
Main Methods:
- Review of scientific literature on natriuretic peptide engineering and drug discovery.
- Analysis of advancements in peptide modification for enhanced efficacy and stability.
- Examination of improved peptide delivery systems for better bioavailability.
- Focus on designer natriuretic peptides currently in clinical trials.
Main Results:
- Peptide engineering has yielded designer natriuretic peptides with superior efficacy, specificity, and resistance to degradation compared to native peptides.
- Improvements in peptide delivery systems have enhanced bioavailability, enabling chronic administration.
- Designer natriuretic peptides demonstrate pleiotropic actions, offering significant therapeutic potential for cardiovascular diseases.
- Several designer natriuretic peptides, including Cenderitide, ANX042, and ZD100, are in clinical trials for heart failure and hypertension.
Conclusions:
- Designer natriuretic peptides represent a significant advancement in cardiovascular therapeutics.
- Chronic delivery strategies combined with engineered peptides offer a novel approach to treating cardiovascular diseases.
- Ongoing clinical trials are evaluating the efficacy and safety of these advanced peptide therapeutics.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.5K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:30Heart Failure V: Medical Management
429
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
429
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
55
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
55
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K